Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Other Gross PP&E Adjustments (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Other Gross PP&E Adjustments readings, the most recent being -$62.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 13.9% year-over-year to -$62.2 million, compared with a TTM value of -$62.2 million through Dec 2025, down 13.9%, and an annual FY2025 reading of -$62.2 million, down 13.9% over the prior year.
  • Other Gross PP&E Adjustments hit -$62.2 million in Q4 2025 for Apellis Pharmaceuticals, down from -$19.7 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was -$14.6 million in Q2 2025, with the low at -$62.2 million in Q4 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$19.8 million (2022), compared with a mean of -$26.5 million.
  • The sharpest move saw Other Gross PP&E Adjustments crashed 69.3% in 2021, then increased 20.68% in 2023.
  • Year by year, Other Gross PP&E Adjustments stood at -$42.3 million in 2021, then dropped by 14.45% to -$48.4 million in 2022, then fell by 0.08% to -$48.5 million in 2023, then decreased by 12.63% to -$54.6 million in 2024, then decreased by 13.9% to -$62.2 million in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$62.2 million, -$19.7 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.